Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

References

• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• RibasATumor immunotherapy directed at PD-1N Engl J Med2012366262517251922658126
   PubMed Web of Science ®Google Scholar
• ChenDSMellmanIOncology meets immunology: the cancer-immunity cycleImmunity201339111023890059
   PubMed Web of Science ®Google Scholar
• DunnGPOldLJSchreiberRDThe three Es of cancer immunoeditingAnnu Rev Immunol20042232936015032581
   PubMed Web of Science ®Google Scholar
• SwannJBSmythMJImmune surveillance of tumorsJ Clin Invest200711751137114617476343
   PubMed Web of Science ®Google Scholar
• RavalRRSharabiABWalkerAJDrakeCGSharmaPTumor immunology and cancer immunotherapy: summary of the 2013 SITC primerJ Immunother Cancer201421424883190
   PubMedGoogle Scholar
• KantoffPWHiganoCSShoreNDIMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• PostowMCallahanMKWolchokJDBeyond cancer vaccines: a reason for future optimism with immunomodulatory therapyCancer J201117537237821952288
   PubMed Web of Science ®Google Scholar
• KirkwoodJMStrawdermanMHErnstoffMSSmithTJBordenECBlumRHInterferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol19961417178558223
   PubMed Web of Science ®Google Scholar
• KirkwoodJMManolaJIbrahimJEastern Cooperative Oncology GroupA pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanomaClin Cancer Res20041051670167715014018
   PubMed Web of Science ®Google Scholar
• SullivanRJLorussoPMFlahertyKTThe intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will beClin Cancer Res201319195283529124089441
   PubMed Web of Science ®Google Scholar
• O’DaySBoasbergPManagement of metastatic melanoma 2005Surg Oncol Clin N Am200615241943716632224
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• SchwartzRHCostimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapyCell1992717106510681335362
   PubMed Web of Science ®Google Scholar
• EgenJGAllisonJPCytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strengthImmunity2002161233511825563
   PubMed Web of Science ®Google Scholar
• ParryRVChemnitzJMFrauwirthKACTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanismsMol Cell Biol200525219543955316227604
   PubMed Web of Science ®Google Scholar
• LeachDRKrummelMFAllisonJPEnhancement of antitumor immunity by CTLA-4 blockadeScience19962715256173417368596936
   PubMed Web of Science ®Google Scholar
• ChambersCAKuhnsMSEgenJGAllisonJPCTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapyAnnu Rev Immunol20011956559411244047
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• FreemanGJLongAJIwaiYEngagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activationJ Exp Med200019271027103411015443
   PubMed Web of Science ®Google Scholar
• ShinTYoshimuraKShinTIn vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responsesJ Exp Med2005201101531154115897272
   PubMed Web of Science ®Google Scholar
• BarberDLWherryEJMasopustDRestoring function in exhausted CD8 T cells during chronic viral infectionNature2006439707768268716382236
   PubMed Web of Science ®Google Scholar
• DongHStromeSESalomaoDRTumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasionNat Med20028879380012091876
   PubMed Web of Science ®Google Scholar
• RosenwaldAWrightGLeroyKMolecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaJ Exp Med2003198685186212975453
   PubMed Web of Science ®Google Scholar
• TaubeJMAndersRAYoungGDColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeSci Transl Med20124127127ra37
   PubMed Web of Science ®Google Scholar
• MarzecMZhangQGoradiaAOncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proc Natl Acad Sci U S A200810552208522085719088198
   PubMed Web of Science ®Google Scholar
• AtefiMAvramisELassenAEffects of MAPK and PI3K pathways on PD-L1 expression in melanomaClin Cancer Res201420133446345724812408
   PubMed Web of Science ®Google Scholar
• ParsaATWaldronJSPannerALoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNat Med2007131848817159987
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res Epub482014
   Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• WolchokJDWeberJSMaioMFour-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trialsAnn Oncol20132482174218023666915
   PubMed Web of Science ®Google Scholar
• WolchokJDJoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar
• OttPAHodiFSRobertCCTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patientsClin Cancer Res201319195300553924089443
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol201432101020103024590637
   PubMed Web of Science ®Google Scholar
• WeberJSKudchadkarRRYuBSafety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanomaJ Clin Oncol201331344311431824145345
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• BergerRRotem-YehudarRSlamaGPhase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignanciesClin Cancer Res200814103044305118483370
   PubMed Web of Science ®Google Scholar
• ArmandPNaglerAWellerEADisabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trialJ Clin Oncol201331334199420624127452
   PubMed Web of Science ®Google Scholar
• WestinJRChuFZhangMSafety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialLancet Oncol2014151697724332512
   PubMed Web of Science ®Google Scholar
• HamidOSosmanJALawrenceDPClinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic melanomaJ Clin Oncol201331Suppl [abstr 9010]
   Google Scholar
• SpigelDRGettingerSNHornLClinical activity, safety and biomarkers of MPDL3208A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)J Clin Oncol201331Suppl [abstr 8008]
   Google Scholar
• ChoDCSosmanJASznolKClinical activity, safety and biomarkers of MPDL3208A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (RCC)J Clin Oncol201331Suppl [abstr 4505]
   Google Scholar
• LutzkyJAntoniaSJBlake-HaskinsAA phase I study of MEDI4736, an anti-PD-L1 antibody, in patients with solid tumorsJ Clin Oncol2014325s [abstr 3001]
   Web of Science ®Google Scholar
• SegalNHAntoniaSJBrahmerJRPreliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibodyJ Clin Oncol2014325s [abstr 3002]
   PubMed Web of Science ®Google Scholar
• HeeryCRO’Sullivan CoyneGHMadanRAPhase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignanciesJ Clin Oncol2014325s [abstr 3064]
   Web of Science ®Google Scholar
• InfanteJRPowderlyJDBurrisHAClinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptorJ Clin Oncol201431Suppl [abstr 3044]
   Google Scholar
• RobertCSchadendorfDMessinaMHodiFSO’DaySMDX010-20 investigatorsEfficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease controlClin Cancer Res20131982232223923444228
   PubMed Web of Science ®Google Scholar
• LipsonEJSharfmanWHDrakeCGDurable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibodyClin Cancer Res201319246246823169436
   PubMed Web of Science ®Google Scholar
• HinoRKabashimaKKatoYTumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanomaCancer201011671757176620143437
   PubMed Web of Science ®Google Scholar